These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

432 related items for PubMed ID: 26136200

  • 41. [Effect of mixing of fine carrier particles on dry powder inhalation property of salbutamol sulfate (SS)].
    Iida K, Leuenberger H, Fueg LM, Müller-Walz R, Okamoto H, Danjo K.
    Yakugaku Zasshi; 2000 Jan; 120(1):113-9. PubMed ID: 10655787
    [Abstract] [Full Text] [Related]

  • 42. The Relationship Between the Permeability and the Performance of Carrier-Based Dry Powder Inhalation Mixtures: New Insights and Practical Guidance.
    Shalash AO, Khalafallah NM, Molokhia AM, Elsayed MMA.
    AAPS PharmSciTech; 2018 Feb; 19(2):912-922. PubMed ID: 29063377
    [Abstract] [Full Text] [Related]

  • 43. Surface Modification of lactose carrier particles using a fluid bed coater to improve fine particle fraction for dry powder inhalers.
    Gong QQ, Tay JYS, Veronica N, Xu J, Heng PWS, Zhang YP, Liew CV.
    Pharm Dev Technol; 2023 Feb; 28(2):164-175. PubMed ID: 36683577
    [Abstract] [Full Text] [Related]

  • 44. An insight into powder entrainment and drug delivery mechanisms from a modified Rotahaler®.
    Sim S, Margo K, Parks J, Howell R, Hebbink GA, Orlando L, Larson I, Leslie P, Ho L, Morton DA.
    Int J Pharm; 2014 Dec 30; 477(1-2):351-60. PubMed ID: 25196720
    [Abstract] [Full Text] [Related]

  • 45. Agglomerate behaviour of fluticasone propionate within dry powder inhaler formulations.
    Le VN, Robins E, Flament MP.
    Eur J Pharm Biopharm; 2012 Apr 30; 80(3):596-603. PubMed ID: 22198291
    [Abstract] [Full Text] [Related]

  • 46. Interaction of Formulation and Device Factors Determine the In Vitro Performance of Salbutamol Sulphate Dry Powders for Inhalation.
    Muddle J, Murnane D, Parisini I, Brown M, Page C, Forbes B.
    J Pharm Sci; 2015 Nov 30; 104(11):3861-3869. PubMed ID: 26220184
    [Abstract] [Full Text] [Related]

  • 47. Effects of particle size and adding sequence of fine lactose on the deposition of salbutamol sulphate from a dry powder formulation.
    Zeng XM, Martin GP, Tee SK, Ghoush AA, Marriott C.
    Int J Pharm; 1999 May 25; 182(2):133-44. PubMed ID: 10341303
    [Abstract] [Full Text] [Related]

  • 48. Dissolution of fine particle fraction from truncated Anderson cascade impactor with an enhancer cell.
    Tay JYS, Liew CV, Heng PWS.
    Int J Pharm; 2018 Jul 10; 545(1-2):45-50. PubMed ID: 29689370
    [Abstract] [Full Text] [Related]

  • 49. Exploring the potential influence of drug charge on downstream deposition behaviour of DPI powders.
    Sun Y, Cui Z, Sun Y, Qin L, Zhang X, Liu Q, Shen X, Yu D, Mao S.
    Int J Pharm; 2020 Oct 15; 588():119798. PubMed ID: 32828976
    [Abstract] [Full Text] [Related]

  • 50. Aerosolization characteristics of dry powder inhaler formulations for the excipient enhanced growth (EEG) application: effect of spray drying process conditions on aerosol performance.
    Son YJ, Worth Longest P, Hindle M.
    Int J Pharm; 2013 Feb 25; 443(1-2):137-45. PubMed ID: 23313343
    [Abstract] [Full Text] [Related]

  • 51. Applications of capsule dosing techniques for use in dry powder inhalers.
    Edwards D.
    Ther Deliv; 2010 Jul 25; 1(1):195-201. PubMed ID: 22816126
    [Abstract] [Full Text] [Related]

  • 52. Improving Dry Powder Inhaler Performance by Surface Roughening of Lactose Carrier Particles.
    Tan BM, Chan LW, Heng PW.
    Pharm Res; 2016 Aug 25; 33(8):1923-35. PubMed ID: 27091033
    [Abstract] [Full Text] [Related]

  • 53. Adhesion forces in interactive mixtures for dry powder inhalers--evaluation of a new measuring method.
    Lohrmann M, Kappl M, Butt HJ, Urbanetz NA, Lippold BC.
    Eur J Pharm Biopharm; 2007 Sep 25; 67(2):579-86. PubMed ID: 17418548
    [Abstract] [Full Text] [Related]

  • 54. Effect of carrier size on the dispersion of salmeterol xinafoate from interactive mixtures.
    Islam N, Stewart P, Larson I, Hartley P.
    J Pharm Sci; 2004 Apr 25; 93(4):1030-8. PubMed ID: 14999738
    [Abstract] [Full Text] [Related]

  • 55. Engineered mannitol ternary additives improve dispersion of lactose-salbutamol sulphate dry powder inhalations.
    Kaialy W, Nokhodchi A.
    AAPS J; 2013 Jul 25; 15(3):728-43. PubMed ID: 23591748
    [Abstract] [Full Text] [Related]

  • 56. The influence of carrier morphology on drug delivery by dry powder inhalers.
    Zeng XM, Martin GP, Marriott C, Pritchard J.
    Int J Pharm; 2000 Apr 25; 200(1):93-106. PubMed ID: 10845690
    [Abstract] [Full Text] [Related]

  • 57. Pharmacokinetics and pharmacodynamics of fluticasone propionate and salmeterol delivered as a combination dry powder from a capsule-based inhaler and a multidose inhaler in asthma and COPD patients.
    Daley-Yates PT, Mehta R, Chan RH, Despa SX, Louey MD.
    J Aerosol Med Pulm Drug Deliv; 2014 Aug 25; 27(4):279-89. PubMed ID: 24074143
    [Abstract] [Full Text] [Related]

  • 58. The effect of engineered mannitol-lactose mixture on dry powder inhaler performance.
    Kaialy W, Larhrib H, Martin GP, Nokhodchi A.
    Pharm Res; 2012 Aug 25; 29(8):2139-56. PubMed ID: 22477070
    [Abstract] [Full Text] [Related]

  • 59. Preparation and evaluation of poly(lactic-co-glycolic acid) microparticles as a carrier for pulmonary delivery of recombinant human interleukin-2: II. In vitro studies on aerodynamic properties of dry powder inhaler formulations.
    Devrim B, Bozkır A, Canefe K.
    Drug Dev Ind Pharm; 2011 Nov 25; 37(11):1376-86. PubMed ID: 21548727
    [Abstract] [Full Text] [Related]

  • 60. Characterisation and deposition studies of recrystallised lactose from binary mixtures of ethanol/butanol for improved drug delivery from dry powder inhalers.
    Kaialy W, Martin GP, Ticehurst MD, Royall P, Mohammad MA, Murphy J, Nokhodchi A.
    AAPS J; 2011 Mar 25; 13(1):30-43. PubMed ID: 21057906
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.